Cargando…

Novel biomarkers for early targeted and individualized treatment in Juvenile Idiopathic Arthritis

BACKGROUND: The programmed cell death protein-1 (PD-1) and its ligands (PD-L 1 and 2) suppress immune responses, thus promoting self-tolerance. Among the immunomodulatory cells, acting through the PD-1 pathway, are the B-regulatory cells (Bregs). The role of the PD-1 pathway in Juvenile Idiopathic A...

Descripción completa

Detalles Bibliográficos
Autores principales: Koutsonikoli, Artemis, Taparkou, Anna, Pratsidou-Gkertsi, Polyxeni, Sgouropoulou, Vassiliki, Dimitroulas, Theodoros, Trachana, Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Mediterranean Journal of Rheumatology (MJR) 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7362122/
https://www.ncbi.nlm.nih.gov/pubmed/32676564
http://dx.doi.org/10.31138/mjr.31.2.230
_version_ 1783559446334537728
author Koutsonikoli, Artemis
Taparkou, Anna
Pratsidou-Gkertsi, Polyxeni
Sgouropoulou, Vassiliki
Dimitroulas, Theodoros
Trachana, Maria
author_facet Koutsonikoli, Artemis
Taparkou, Anna
Pratsidou-Gkertsi, Polyxeni
Sgouropoulou, Vassiliki
Dimitroulas, Theodoros
Trachana, Maria
author_sort Koutsonikoli, Artemis
collection PubMed
description BACKGROUND: The programmed cell death protein-1 (PD-1) and its ligands (PD-L 1 and 2) suppress immune responses, thus promoting self-tolerance. Among the immunomodulatory cells, acting through the PD-1 pathway, are the B-regulatory cells (Bregs). The role of the PD-1 pathway in Juvenile Idiopathic Arthritis (JIA) has not been adequately studied. AIMS OF THE STUDY: To investigate the immunophenotypic profile of T- and B-cells and the activity of the PD-1 pathway in JIA patients. More specifically, we will examine the levels of: a) the soluble form of PD-1 (sPD-1), b) Bregs; and the expression levels of: c) PD-1 on CD4+ and CD8+ T-cells, d) PD-L1 on Bregs and CD19+ B-cells, in blood and synovial fluid samples, at various stages of the disease (onset, relapse, remission, on or off treatment). The above biomarkers will be investigated for correlation with JIA activity. METHODS: A case-control study of JIA patients (expected number: 60) and healthy controls (n: 20). Total expected number of samples: 100 of peripheral blood, 120 of serum (solely for soluble markers) and 60 of synovial fluid. The patients’ demographic data and treatment will be recorded. JIA will be classified according to the ILAR and the recently proposed PReS/PRINTO criteria. JIA activity will be assessed using the JADAS-10 tool. The biomarkers will be determined using multiparametric-polychromatic flow cytometry (quintuple fluorescence protocol) and immunoenzymatic assay ELISA. ANTICIPATED BENEFITS: Further elucidation of the immunophenotypic expression and variation of the abovementioned molecules and cells during active inflammation and remission in JIA. Thereby, the present study is expected to contribute to: a) the modern research and understanding of the confirmed immune dysfunction at the cellular level, which leads to the development of serious autoimmune diseases in childhood, such as JIA, and b) the search for biomarkers that could be targets of early “intelligent” treatment and thereby could support the implementation of precision-medicine. The early diagnosis and targeted treatment of JIA are crucial for the maintenance of normal physical functioning and the psychosocial balance of the still growing adolescent/child.
format Online
Article
Text
id pubmed-7362122
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher The Mediterranean Journal of Rheumatology (MJR)
record_format MEDLINE/PubMed
spelling pubmed-73621222020-07-15 Novel biomarkers for early targeted and individualized treatment in Juvenile Idiopathic Arthritis Koutsonikoli, Artemis Taparkou, Anna Pratsidou-Gkertsi, Polyxeni Sgouropoulou, Vassiliki Dimitroulas, Theodoros Trachana, Maria Mediterr J Rheumatol Research Protocol BACKGROUND: The programmed cell death protein-1 (PD-1) and its ligands (PD-L 1 and 2) suppress immune responses, thus promoting self-tolerance. Among the immunomodulatory cells, acting through the PD-1 pathway, are the B-regulatory cells (Bregs). The role of the PD-1 pathway in Juvenile Idiopathic Arthritis (JIA) has not been adequately studied. AIMS OF THE STUDY: To investigate the immunophenotypic profile of T- and B-cells and the activity of the PD-1 pathway in JIA patients. More specifically, we will examine the levels of: a) the soluble form of PD-1 (sPD-1), b) Bregs; and the expression levels of: c) PD-1 on CD4+ and CD8+ T-cells, d) PD-L1 on Bregs and CD19+ B-cells, in blood and synovial fluid samples, at various stages of the disease (onset, relapse, remission, on or off treatment). The above biomarkers will be investigated for correlation with JIA activity. METHODS: A case-control study of JIA patients (expected number: 60) and healthy controls (n: 20). Total expected number of samples: 100 of peripheral blood, 120 of serum (solely for soluble markers) and 60 of synovial fluid. The patients’ demographic data and treatment will be recorded. JIA will be classified according to the ILAR and the recently proposed PReS/PRINTO criteria. JIA activity will be assessed using the JADAS-10 tool. The biomarkers will be determined using multiparametric-polychromatic flow cytometry (quintuple fluorescence protocol) and immunoenzymatic assay ELISA. ANTICIPATED BENEFITS: Further elucidation of the immunophenotypic expression and variation of the abovementioned molecules and cells during active inflammation and remission in JIA. Thereby, the present study is expected to contribute to: a) the modern research and understanding of the confirmed immune dysfunction at the cellular level, which leads to the development of serious autoimmune diseases in childhood, such as JIA, and b) the search for biomarkers that could be targets of early “intelligent” treatment and thereby could support the implementation of precision-medicine. The early diagnosis and targeted treatment of JIA are crucial for the maintenance of normal physical functioning and the psychosocial balance of the still growing adolescent/child. The Mediterranean Journal of Rheumatology (MJR) 2020-06-01 /pmc/articles/PMC7362122/ /pubmed/32676564 http://dx.doi.org/10.31138/mjr.31.2.230 Text en © 2020 The Mediterranean Journal of Rheumatology (MJR) http://creativecommons.org/licenses/by/4.0/ This work is licensed under and Creative Commons Attribution-NonCommercial 4.0 International License.
spellingShingle Research Protocol
Koutsonikoli, Artemis
Taparkou, Anna
Pratsidou-Gkertsi, Polyxeni
Sgouropoulou, Vassiliki
Dimitroulas, Theodoros
Trachana, Maria
Novel biomarkers for early targeted and individualized treatment in Juvenile Idiopathic Arthritis
title Novel biomarkers for early targeted and individualized treatment in Juvenile Idiopathic Arthritis
title_full Novel biomarkers for early targeted and individualized treatment in Juvenile Idiopathic Arthritis
title_fullStr Novel biomarkers for early targeted and individualized treatment in Juvenile Idiopathic Arthritis
title_full_unstemmed Novel biomarkers for early targeted and individualized treatment in Juvenile Idiopathic Arthritis
title_short Novel biomarkers for early targeted and individualized treatment in Juvenile Idiopathic Arthritis
title_sort novel biomarkers for early targeted and individualized treatment in juvenile idiopathic arthritis
topic Research Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7362122/
https://www.ncbi.nlm.nih.gov/pubmed/32676564
http://dx.doi.org/10.31138/mjr.31.2.230
work_keys_str_mv AT koutsonikoliartemis novelbiomarkersforearlytargetedandindividualizedtreatmentinjuvenileidiopathicarthritis
AT taparkouanna novelbiomarkersforearlytargetedandindividualizedtreatmentinjuvenileidiopathicarthritis
AT pratsidougkertsipolyxeni novelbiomarkersforearlytargetedandindividualizedtreatmentinjuvenileidiopathicarthritis
AT sgouropoulouvassiliki novelbiomarkersforearlytargetedandindividualizedtreatmentinjuvenileidiopathicarthritis
AT dimitroulastheodoros novelbiomarkersforearlytargetedandindividualizedtreatmentinjuvenileidiopathicarthritis
AT trachanamaria novelbiomarkersforearlytargetedandindividualizedtreatmentinjuvenileidiopathicarthritis